Selective label-free electrochemical impedance measurement of glycated haemoglobin on 3-aminophenylboronic acid-modified eggshell membranes
Selective label-free electrochemical impedance measurement of glycated haemoglobin on 3-aminophenylboronic acid-modified eggshell membranes
复制标题
DOI：
10.1007/s00216-015-8680-8
复制
发表时间：
2015-07-01
影响因子：
4.3
通讯作者：
Laiwattanapaisal, Wanida
中科院分区：
文献类型：
--
作者：
Boonyasit, Yuwadee;Heiskanen, Arto;Laiwattanapaisal, Wanida
我们提出了一种新的替代方法，长期使用蛋壳膜（ESM）作为一种新的固定化平台的糖化血红蛋白（HbA 1c），一个重要的临床指标，糖尿病患者的贫血状态的选择性无标记的电化学传感。由于一种新的3-氨基苯基硼酸修饰的ESM的独特功能，通过顺式二醇相互作用获得选择性结合。这种新开发的设备提供了作为基于亲和膜的生物传感器的临床适用性，用于在临床相关范围（2.3 - 14%）内识别HbA 1c，检测限为0.19%。所提出的膜基生物传感器也表现出良好的重现性。当分析正常和异常HbA 1c水平时，运行内变异系数分别为1.68和1.83%。批间变异系数分别为1.97和2.02%。结果表明，该方法可实现HbA 1c的准确、选择性测定。与市售HbA 1c试剂盒相比，结果表明两种技术之间具有良好的一致性（n = 15），证明了该传感器用于监测血糖控制的临床适用性。因此，使用所提出的基于膜的生物传感器的这种低成本感测平台对于护理点诊断是理想的。
We propose a novel alternative approach to long-term glycaemic monitoring using eggshell membranes (ESMs) as a new immobilising platform for the selective label-free electrochemical sensing of glycated haemoglobin (HbA1c), a vital clinical index of the glycaemic status in diabetic individuals. Due to the unique features of a novel 3-aminophenylboronic acid-modified ESM, selective binding was obtained via cis-diol interactions. This newly developed device provides clinical applicability as an affinity membrane-based biosensor for the identification of HbA1c over a clinically relevant range (2.3 - 14 %) with a detection limit of 0.19 %. The proposed membrane-based biosensor also exhibited good reproducibility. When analysing normal and abnormal HbA1c levels, the within-run coefficients of variation were 1.68 and 1.83 %, respectively. The run-to-run coefficients of variation were 1.97 and 2.02 %, respectively. These results demonstrated that this method achieved the precise and selective measurement of HbA1c. Compared with a commercial HbA1c kit, the results demonstrated excellent agreement between the techniques (n = 15), demonstrating the clinical applicability of this sensor for monitoring glycaemic control. Thus, this low-cost sensing platform using the proposed membrane-based biosensor is ideal for point-of-care diagnostics.